Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

CRANBURY, N.J., Feb. 16, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011. In addition, the Company announced that it will present encouraging data from its preclinical studies evaluating the co-administration of pharmacological chaperones with enzyme replacement therapy (ERT) in Fabry disease, as well as from preclinical studies examining the use of pharmacological chaperones for the treatment of genetically defined subpopulations of Parkinson's disease and Alzheimer's disease.

Preliminary Data Update from Phase 2 Long-Term Extension Study of Migalastat HCl for Fabry DiseaseTwenty-six subjects completed either 12 or 24 weeks of treatment with migalastat HCl during the initial Phase 2 studies and 23 subjects enrolled in a separate, long-term extension study designed to evaluate the long-term safety and efficacy of migalastat HCl. Over the course of the initial Phase 2 and extension studies, 15 subjects have been treated with migalastat HCl for more than 3 years and 7 subjects have been treated with migalastat HCl for more than 4 years. Seventeen subjects continue to receive treatment in the ongoing extension study.

During the course of the extension study, treatment with migalastat HCl has continued to be generally well tolerated, with no drug-related serious adverse events. The most common adverse events have been headache, arthralgia, diarrhea and fatigue.

Renal function continues to be evaluated by two measures in the extension study, estimated glomerular filtration rate (eGFR) and 24-hour urine protein. Preliminary data indicate that eGFR has remained stable out to 3-4 years
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Aug. 18, 2014 BioElectronics Corporation ... consumer medical devices said that its EVP ... by CEOLIVE.TV as part of its Executive ... is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... to investors the unique advantages of BioElectronics ...
(Date:8/18/2014)... UPTON, NYElectronic devices with unprecedented efficiency and ... materials that use built-in electric polarizations to ... magnets inside most popular data-driven technology. But ... stumbling blocks, including a curious habit of ... at the U.S. Department of Energy,s Brookhaven ...
(Date:8/18/2014)... YORK , August 18, 2014 ... published by Transparency Market Research "Life Science Reagents ... Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and ... and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- ... Forecast, 2013 - 2019", the global life science ...
(Date:8/18/2014)... Aug. 18, 2014 TNI BioTech, Inc. (OTC-BB: ... the manufacturing and marketing of innovative therapies for autoimmune ... is providing a second notice of TNI BioTech,s annual ... the announcement, Noreen Griffin , founder and CEO ... for your participation in the Annual Meeting. On behalf ...
Breaking Biology Technology:BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... (TSX: GEN),a company focused on developing molecular diagnostic ... early detection of diseases and personalized,health management, today ... design and development of in-vitro diagnostic (IVD) test,kits ... in a laboratory,setting, has met the requirements of ...
... Sweden, March 11 Mentice AB, a leading,supplier of ... has recently appointed James Ruscoe as Chairman of the ... Mr. Ruscoe graduated from Oxford University and brings ... He also serves as CEO and,board member of several ...
... March 11 Proteome Systems Ltd. (ASX: PXL),CEO ... a panel with world health,leaders in Washington DC ... the Bill & Melinda Gates Foundation and organised ... Biotechnology Industry Organization.,[March 10-12, 2008]., http://pgh.bio.org/opencms/PGH/2008/program/program.jsp , ...
Cached Biology Technology:GeneNews receives ISO 13485 accreditation 2Mentice AB Announces Leadership Changes Within Its Worldwide Operations 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 3
(Date:8/20/2014)... have discovered that acral melanomas the rare type of ... are genetically distinct from other more common types of skin ... the journal Pigment Cell & Melanoma Research . , ... soles of the feet, nail-beds and other hairless parts of ... not caused by UV damage from the sun. , The ...
(Date:8/20/2014)... rugs and plastic bags could one day be made ... petroleum, scientists are now reporting. The novel process they ... deal with its agricultural and plastic waste problems, appear ... Athanassiou, Ilker S. Bayer and colleagues at the Italian ... constantly growing. In 2012, its production reached 288 million ...
(Date:8/20/2014)... (PS1) absorbs light and its energy is finally ... biomass. Photovoltaic devices, mostly build from silicon based ... One approach for the development of cheaper and ... the isolated membrane protein complexes of photosynthesis. Prof. ... PS1 from thermophilic cyanobacteria that live in a ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... -- A new study led by Florida State University ... more flowers in response to only slight increases in ... clouds and rainfall affect the number of flowers that ... an effect over short-term seasonal growth, but longer-term changes ...
... Small and large-scale farmers in Riau province, Sumatra, have ... and parts of Malaysia. But scientists in Indonesia have ... buy unregulated access to land for oil palm and ... Scientists at the World Agroforestry Centre, who have been ...
... 8 July 2013: Egg donation is now one of ... treatment. Because this growing trend may circumvent regulations at ... also become one of the most controversial. Yet little ... eggs in overseas clinics - their characteristics, their motivation ...
Cached Biology News:Temperature increases causing tropical forests to blossom, according to study 2Less haze in Singapore as the cause becomes clearer and more complex 2Egg donation in European clinics: Why do women do it? 2Egg donation in European clinics: Why do women do it? 3
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
Red Standard is sodium salt of resorufin....
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Biology Products: